Unmet Needs Persist for Patients with Melanoma
Source: Targeted Oncology, July 2024
Melanoma was the topic of some of the most exciting abstracts at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting. Among these was the practice-changing NADINA trial (NCT04949113) investigating neoadjuvant ipilimumab plus nivolumab vs adjuvant nivolumab in macroscopic stage III melanoma.
However, even with these developments, unmet needs still persist for patients with advanced melanoma. These include the need for more effective treatments, improved management for adverse effects, psychosocial support, information and education, and access to care.
Here Maya Dimitrova, MD, medical oncologist at the Perlmutter Cancer Institute at NYU Langone Heatlh, discusses some of the unmet needs in melanoma and how abstracts presented at the 2024 ASCO Annual Meeting address these.